Title:
USE OF COMBINATION OF ACTIVATED T CELL AND BLOCKING ANTIBODY IN PREPARATION OF ANTI-TUMOR MEDICAMENT, AND ANTI-TUMOR MEDICAMENT
Document Type and Number:
WIPO Patent Application WO/2024/001530
Kind Code:
A1
Abstract:
Disclosed are use of a combination of an activated T cell and a blocking antibody in the preparation of an anti-tumor medicament, and the anti-tumor medicament. The activated T cell is obtained by: separating T cells from the tissue or body fluid of a patient, performing sorting with an anti-human CD3 antibody to obtain a CD3+T cell, and then performing stimulation for activation with the anti-human CD3 antibody, an anti-human CD28 antibody and human IL-2. The blocking antibody is any one or more of an anti-SIA-IgG antibody, an anti-Siglec-7 antibody, an anti-Siglec-9 antibody, an anti-Siglec-10 antibody and an anti-PD-1 antibody. The combination is more significantly effective in treatment than the activated T cell or the blocking antibody alone, indicating that there is a synergy between the blocking antibody and the activated T cell, so that a better anti-tumor effect is achieved.
More Like This:
Inventors:
QIU XIAOYAN (CN)
FAN TIANRUI (CN)
HE ZHIQIAO (CN)
FAN TIANRUI (CN)
HE ZHIQIAO (CN)
Application Number:
PCT/CN2023/092933
Publication Date:
January 04, 2024
Filing Date:
May 09, 2023
Export Citation:
Assignee:
BEIJING AISAIJI BIOPHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K39/395; A61K35/17; A61P35/00; C12N5/0783
Foreign References:
| CN114796483A | 2022-07-29 | |||
| CN106729705A | 2017-05-31 | |||
| CN108699158A | 2018-10-23 | |||
| CN110713978A | 2020-01-21 | |||
| CN113913385A | 2022-01-11 | |||
| CN114031688A | 2022-02-11 | |||
| CN106834228A | 2017-06-13 | |||
| CN110540960A | 2019-12-06 | |||
| CN109789206A | 2019-05-21 |
Other References:
LIM JACKWEE, SARI-AK DUYGU, BAGGA TANAYA: "Siglecs as Therapeutic Targets in Cancer", BIOLOGY, MDPI, CH, vol. 10, no. 11, 13 November 2021 (2021-11-13), CH , pages 1178, XP093122064, ISSN: 2079-7737, DOI: 10.3390/biology10111178
IBARLUCEA-BENITEZ ITZIAR, WEITZENFELD POLINA, SMITH PATRICK, RAVETCH JEFFREY V.: "Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 118, no. 26, 29 June 2021 (2021-06-29), pages e2107424118, XP093122065, ISSN: 0027-8424, DOI: 10.1073/pnas.2107424118
IBARLUCEA-BENITEZ ITZIAR, WEITZENFELD POLINA, SMITH PATRICK, RAVETCH JEFFREY V.: "Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 118, no. 26, 29 June 2021 (2021-06-29), pages e2107424118, XP093122065, ISSN: 0027-8424, DOI: 10.1073/pnas.2107424118
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: